Amphetamine: adverse event reports filed with FDA

4,388

reports as suspect product

0% of all reports · about 196 a year

486

reports, 12 months to June 2026

597 in the 12 months before

96.1%

marked serious by the reporter

45% across the class

64.6%

record death among outcomes, as reported

2,833 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Amphetamine reports recording the termmedian drug in central nervous system stimulant

1. Toxicity to various agentspoisoning or toxic effect of one or more substances34%1,493
2. Drug abusemisuse of a medicine28.1%1,235
3. Completed suicidedeath by suicide14.7%643
4. Overdosea dose above the recommended amount7.5%331
5. Deaththe patient died; cause not stated by this term7.5%328
6. Cardiac arrestthe heart stopped6.1%267
7. Cardio-respiratory arrestthe heart and breathing stopped5.9%257
8. Respiratory arrestbreathing stopped4.7%207
9. Substance abuse3.5%154
10. Drug dependencedependence on a medicine3.4%151
11. Drug interactionan interaction between medicines3.3%145
12. Poisoning3.1%135
13. Intentional product misusedeliberate use not as intended2.6%113
14. Pulmonary oedemafluid in the lungs2.2%95
15. Drug ineffectivethe medicine did not work as expected2.1%94
16. Somnolencedrowsiness2.1%94
17. Intentional overdosea deliberate overdose2.1%92
18. Serotonin syndrometoo much serotonin activity, with agitation, fever and tremor1.8%81
19. Tachycardiafast heart rate1.8%81
20. Rhabdomyolysismuscle breakdown1.8%80
21. Brain oedema1.8%78
22. Accidental overdosean accidental overdose1.7%75
23. Aggressionaggressive behaviour1.6%70
24. Agitationrestlessness1.6%70
25. Drug diversion1.6%70
26. Suicide attempta suicide attempt1.4%63
27. Respiratory depressionslow or shallow breathing1.4%62
28. Anxietyanxiety1.4%61
29. Unresponsive to stimuli1.4%61
30. Headachehead pain1.3%55

Top 30 of 611 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 26 drugs in the central nervous system stimulant class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 109,804 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 61.7% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 4,388 reports.

Drugs most often listed in the same reports

Other products listed in reports where Amphetamine is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the central nervous system stimulant class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Amphetamine as a suspect or interacting product; reports listing it only as a concomitant medication (1,590) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.